Petra Bělohlávková

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

Uwe Platzbecker, Valeria Santini, Pierre Fenaux et al. · The Lancet · 2023 · 132 citations

Medicine, Hematology, Pharmacology +8

Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia

J Voglová, Edgar Faber, Hana Klamová et al. · Neoplasma · 2011 · 30 citations

Medicine, Hematology, Oncology +15

A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes

Jaroslav Čermák, Anna Jonášová, Jana Vondráková et al. · Leukemia Research · 2013 · 27 citations

Medicine, Hematology, Pharmacology +12

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment

Monika Jaruskova, Nikola Čuřík, Rajna Hercog et al. · Journal of Experimental & Clinical Cancer Research · 2017 · 27 citations · Full text

Life Sciences, Genetics, Molecular Genetics +16

The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients

Petra Bělohlávková, Filip Vrbacký, J Voglová et al. · Archives of Medical Science · 2018 · 17 citations · Full text

Veterinary Medicine, Pharmacokinetics, Pharmacology +16